{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:34:02Z","timestamp":1648622042068},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1245\/s10434-019-07890-y","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T21:14:56Z","timestamp":1571174096000},"page":"4244-4245","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: A Negative Axillary Clinical Exam Adequately Identifies Clinically Node-Positive Patients who Downstage After NAC and are Candidates for SLNB"],"prefix":"10.1245","volume":"26","author":[{"given":"Tracy-Ann","family":"Moo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"7890_CR1","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines oncology\u2014breast cancer (Version 3.2018). 2018 [January 28, 2018]; Available at: \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n\n."},{"issue":"3","key":"7890_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364.","journal-title":"J Clin Oncol."},{"issue":"10","key":"7890_CR3","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","volume":"20","author":"TJ Hieken","year":"2013","unstructured":"Hieken TJ, Boughey JC, Jones KN, Shah SS, Glazebrook KN. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20(10):3199\u2013204.","journal-title":"Ann Surg Oncol."},{"issue":"30","key":"7890_CR4","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","volume":"33","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the american college of surgeons oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386\u201393.","journal-title":"J Clin Oncol."},{"key":"7890_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07867-x","author":"T-A Moo","year":"2019","unstructured":"Moo T-A, Jochelson MS, Zabor EC, et al. Is clinical exam of the axilla sufficient to select node-positive patients who downstage after NAC for SLNB? A comparison of the accuracy of clinical exam versus MRI. Ann Surg Oncol. 2019. \nhttps:\/\/doi.org\/10.1245\/s10434-019-07867-x\n\n.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07890-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07890-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07890-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:07:35Z","timestamp":1602630455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07890-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":5,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7890"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07890-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Monica Morrow has received speaking honoraria from Genomic Health and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}